5,6,7,8-四氢咪唑并[1,2-a]吡啶-2-羧酸乙酯 | 67286-71-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 5,6,7,8-四氢咪唑并[1,2-a]吡啶-2-羧酸乙酯
• 中文别名: 5,6,7,8-四氢咪唑并[1,2-A]吡啶-2-羧酸乙酯
• 英文名称: ethyl imidazo-<1,2a>-5,6,7,8-tetrahydropyridine-2-carboxylate
• 英文别名: ethyl 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylate；5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester
• CAS: 67286-71-9
• 化学式: C₁₀H₁₄N₂O₂
• 分子量: 194.233
• InChiKey: AAEXPDXMEFVCBC-UHFFFAOYSA-N

物化性质

• 熔点：
  59-63 °C
• 沸点：
  367.4±15.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5,6,7,8-四氢咪唑并[1,2-a]吡啶-2-羧酸乙酯 在 肼 作用下， 以 乙醇 、 水 为溶剂， 生成 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid hydrazide
  参考文献：
  名称：

  Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives

  摘要：

  Even though there are new classes of compounds now frequently used in treatment of fungal infections, the density of deeply invasive candidiasis has increased at least 10-fold during the past decade. Furthermore, many infections due to Candida species are actually refractory to antifungal therapy. In this present study, it was aimed to synthesize, new hydrazide derivatives of tetrahydroimidazo[1,2-a]pyridine and evaluate their anticandidal activity and cytotoxicity in vitro. The reaction of tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid hydrazides with various benzaldehydes gave tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid benzylidene hydrazide derivatives. The chemical structures of the compounds were elucidated and confirmed by IR, H-1 NMR, MS-FAB(+) spectroscopy and elemental analyses. Eight new tetrahydroimidazo[1,2-a]pyridine derivatives were synthesized and screened for their antifungal effects against a panel of ten human pathogenic Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida utilis, and Candida zeylanoides using agar diffusion and broth microdilution assays, respectively. Furthermore, their cytotoxicity was tested against six mammalian cell lines. Among the analogues, the compound 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid-(4-cyanobenzylidene) showed very strong inhibitory activity (up to MIC 0.016 mg/mL) against the screened Candida species. The same compound showed no in vitro toxicity up to 25 mu g/mL concentration suggesting that its antifungal activity (MICs 0.016-1 mg/mL) is selective. (C) 2009 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2009.12.023
• 作为产物：
  描述：

  咪唑吡啶-2-羧酸乙酯 在 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 16.0h， 以86.81%的产率得到5,6,7,8-四氢咪唑并[1,2-a]吡啶-2-羧酸乙酯
  参考文献：
  名称：

  [EN] PYRIMIDONE DERIVATIVES CONTAINING TWO FUSED BICYCLIC RINGS
  [FR] DÉRIVÉS DE PYRIMIDONE CONTENANT DEUX CYCLES BICYCLIQUES FUSIONNÉS

  摘要：

  该发明涉及一种化合物，其化学式为(I)，其中变量在说明书中定义。它还涉及包括化合物(I)的杀虫混合物；将化合物(I)用作农药的农业化学农药；一种用于对抗或控制无脊椎动物害虫的方法，一种用于保护生长中的植物免受无脊椎动物害虫攻击或侵害的方法，包含化合物(I)的种子；将化合物(I)用于保护生长中的植物免受无脊椎动物害虫攻击或侵害的用途；以及一种用于治疗或保护动物免受无脊椎动物害虫侵害或感染的方法。

  公开号：

  WO2021099240A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE PRMT5
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019102494A1

  公开（公告）日：2019-05-31

  The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

  公式I、公式Ia和公式Ib的化合物以及它们的类似物、互变异构体、对映异构体、多态性、水合物、溶剂化物、药物可接受的盐、药物组合物、代谢物和前药在本文件中进行了描述。这些化合物抑制PRMT5，并可作为治疗或改善与细胞生长相关的疾病，如恶性肿瘤、精神分裂症、阿尔茨海默病、帕金森病等的治疗或改善剂。
• Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors
  申请人：Mansour Tarek Suhayl

  公开号：US20100063023A1

  公开（公告）日：2010-03-11

  Provided is a β-lactamase antibiotic and a compound of formula I, a process of producing the compound, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.

  本文提供了一种β-内酰胺酶抗生素和一种I式化合物，以及制备该化合物的过程、制药组合物及其用于治疗患有细菌感染或疾病的患者。
• Base-catalyzed transformations of iminium phenylhydrazones
  作者：C.B. Kanner、U.K. Pandit

  DOI：10.1016/s0040-4020(01)98869-6

  日期：1981.1

  phenyldiazonium fluoroborate to give iminium phenylhydrazone salts which, without isolation, can be converted by a base-catalysed reaction to imidazole derivatives. The latter reaction is critically dependent upon the nature of the base-component of the enamine ester. The mechanism of imidazole formation involves the following sequence of steps: (a) deprotonation of the iminium salt, (b) a symmetry-allowed 1

  β-烯胺酯与氟硼酸苯基重氮反应生成亚氨基苯基hydr盐，该without盐无需分离即可通过碱催化反应转化为咪唑衍生物。后者的反应主要取决于烯胺酯的碱组分的性质。咪唑形成的机理涉及以下步骤：（a）亚胺盐的去质子化；（b）甜菜碱中间体的对称允许的1,5-偶极环化作用；（c）随后消除苯胺，并伴随芳香化作用。讨论了反应的范围，该方法是合成咪唑衍生物的简便方法。
• NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME
  申请人：Kaken Pharmaceutical Co., Ltd.

  公开号：EP3851436A1

  公开（公告）日：2021-07-21

  A compound selectively inhibiting Nav1.7 over Nav1.5 is provided. A heteroaromatic amide derivative or salt thereof showing high efficacy for various diseases associated with Nav1.7 such as pain, represented by the general formula (I) [wherein, X1-X2 is N-C or C-N, Y1 , Y2, Y3 and Y4 are -CH2-, -CR4aH- or -O- and so on, Z1 is-O- and so on, ring A is a 3- to 7-membered monocyclic aromatic ring and so on, R1a and R1b are a hydrogen atom or a halogen atom and so on, R2 is a hydrogen atom and so on, R3a, R3b and R3c are a hydrogen atom or an optionally substituted C1-C6 haloalkyl group and so on, R4a, R4b and R4c are, an optionally substituted C1-C6 haloalkyl group or C1-C6 haloalkoxy group and so on, R5a is a hydrogen atom and so on, R5a and R5b together form -CH2O- and so on, R6a and R6b are a hydrogen atom and so on, n is 1 or 2.].

  提供了一种选择性抑制 Nav1.7 而非 Nav1.5 的化合物。 一种杂芳香族酰胺衍生物或其盐，对与 Nav1.7 相关的各种疾病（如疼痛）有很好的疗效，由通式（I）表示 [其中，X1-X2 是 N-C 或 C-N，Y1、Y2、Y3 和 Y4 是 -CH2-、-CR4aH- 或 -O-等，Z1 是-O-等，环 A 是 3 至 7 元单环芳香环等，R1a 和 R1b 是氢原子或卤素原子等，R2 是氢原子等，R3a、R3b和R3c是氢原子或任选取代的C1-C6卤代烷基等，R4a、R4b和R4c是任选取代的C1-C6卤代烷基或C1-C6卤代烷氧基等，R5a是氢原子等，R5a和R5b共同形成-CH2O-等，R6a和R6b是氢原子等，n是1或2。].
• HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
  申请人：JUBILANT EPISCRIBE LLC

  公开号：US20210371431A1

  公开（公告）日：2021-12-02

  The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.